Search Results for: -trrxht.html

COOKIE POLICY Cookies are small text files that are placed on your device by websites that you visit. They are used to make websites work, or work more efficiently, as well as to provide information to the owners of the website. Our website uses strictly necessary cookies, functional cookies and tracking and performance cookies. Strictly

ACCESSIBILITY STATEMENT OUR COMMITMENT TO ACCESSIBILITY Actuate is committed to making our website accessible to everyone. We have built our website in a manner to work with assistive technologies using the Worldwide Web Consortium’s Website Content Accessibility Guidelines. Actuate continues to evaluate its website to maintain and expand its accessibility for all visitors. FEEDBACK If

CONTACT US If you would like to partner with us, have media inquiries, or simply want to learn more, we want to hear from you. Fill out the form below to get in touch. US ADDRESS 1751 River Run, Suite 400 Fort Worth, TX 76107 EMAIL info@actuatetherapeutics.com EU ADDRESS The Black Church St. Mary’s Place

CAREERS We are pushing further, discovering more, and redefining treatment expectations for patients and providers. But as passionate as we are about our work, we’re equally passionate about doing everything with integrity, ethics, and inclusion. Careers We live, breathe, and sleep scientific innovation. It’s the “why” behind everything we do. If you are driven by

MEDIA PARTNERING As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations. <    COLLABORATE WITH US    >

CLINICAL TRIALS Pancreatic Cancer About 84,000 people in the U.S. are living with pancreatic cancer, based on a 2018 estimate. In the U.S., only about 10% of patients live for at least 5 years after being diagnosed with pancreatic cancer, and about 48,000 patients were predicted to die of pancreatic cancer in 2021. Pancreatic cancer

PIPELINE CLINICAL TRIALS If you or a loved one are living with cancer, and you’re interested in learning about our clinical trials we currently have open, click below to learn more. <    SEE OUR TRIALS    >

OUR SCIENCE THE TARGET GSK-3β has long been an attractive target in cancer therapy, but previous drug candidates developed to inhibit GSK-3β have been limited by poor pharmaceutical characteristics and/or significant adverse effects in patients, limiting their clinical utility. The Function of GSK-3β GSK-3β is an enzyme that regulates a number of intersecting biological pathways

TIMELINE 2024   December 17, 2024 Positive Interim Phase 2 Data of Elraglusib in pancreatic cancer August 14, 2024 Initial Public Offering August 1, 2024 FDA Orphan Drug Designation for Elraglusib  February 9, 2024 The Last Patient’s First Dose of Elraglusib in pancreatic cancer  January 2024 Completion of Enrollment in Phase 2 clinical study in